Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 3
2001 3
2002 3
2003 4
2004 2
2005 2
2006 2
2009 2
2010 3
2011 1
2012 5
2013 4
2015 5
2016 3
2017 5
2019 1
2020 5
2021 7
2022 4
2023 4
2024 5
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suárez C, Chang CH, Roghmann F, Özgüroğlu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS; NIAGARA Investigators. Powles T, et al. N Engl J Med. 2024 Nov 14;391(19):1773-1786. doi: 10.1056/NEJMoa2408154. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282910 Clinical Trial.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Bellmunt J, et al. N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17. N Engl J Med. 2017. PMID: 28212060 Free PMC article. Clinical Trial.
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer.
Catto JWF, Tran B, Rouprêt M, Gschwend JE, Loriot Y, Nishiyama H, Redorta JP, Daneshmand S, Hussain SA, Cutuli HJ, Procopio G, Guadalupi V, Vasdev N, Naini V, Crow L, Triantos S, Baig M, Steinberg G; THOR-2 Cohort 1 Investigators. Catto JWF, et al. Ann Oncol. 2024 Jan;35(1):98-106. doi: 10.1016/j.annonc.2023.09.3116. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871701 Free article. Clinical Trial.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
Immunotherapy in cervix cancer.
Attademo L, Tuninetti V, Pisano C, Cecere SC, Di Napoli M, Tambaro R, Valabrega G, Musacchio L, Setola SV, Piccirillo P, Califano D, Spina A, Losito S, Greggi S, Pignata S. Attademo L, et al. Among authors: tambaro r. Cancer Treat Rev. 2020 Nov;90:102088. doi: 10.1016/j.ctrv.2020.102088. Epub 2020 Aug 7. Cancer Treat Rev. 2020. PMID: 32827839 Review.
Endometrial cancer in the elderly: Characteristics, prognostic and risk factors, and treatment options.
Forte M, Cecere SC, Di Napoli M, Ventriglia J, Tambaro R, Rossetti S, Passarelli A, Casartelli C, Rauso M, Alberico G, Mignogna C, Fiore F, Setola SV, Troiani T, Pignata S, Pisano C. Forte M, et al. Among authors: tambaro r. Crit Rev Oncol Hematol. 2024 Dec;204:104533. doi: 10.1016/j.critrevonc.2024.104533. Epub 2024 Oct 22. Crit Rev Oncol Hematol. 2024. PMID: 39442900 Review.
Oligometastatic prostate cancer treatment.
Rossetti S, Di Napoli M, Pisano C, C Cecere S, Tambaro R, Ventriglia J, Passarelli A, Iovane G, Feroce F, Lastoria S, Di Gennaro F, Muto P, Borzillo V, Di Franco R, Perdonà S, Quarto G, Pignata S. Rossetti S, et al. Among authors: tambaro r. Future Oncol. 2021 Oct;17(29):3893-3899. doi: 10.2217/fon-2021-0126. Epub 2021 Jul 23. Future Oncol. 2021. PMID: 34296622
The emerging role of PARP inhibitors in prostate cancer: A narrative review.
Lobianco L, Calvanese G, D'Ausilio D, Rossetti S, Cecere SC, Ventriglia J, Pisano C, Tambaro R, Napoli MD, Passarelli A, Roma C, Luca A, Sepe F, Cozzolino S, Perri E, Lamia MR, Moccia C, Pignata S. Lobianco L, et al. Among authors: tambaro r. Cancer Treat Rev. 2025 Nov;140:103000. doi: 10.1016/j.ctrv.2025.103000. Epub 2025 Jul 25. Cancer Treat Rev. 2025. PMID: 40848312 Free article. Review.
Treatment of recurrent epithelial ovarian cancer.
Pignata S, Pisano C, Di Napoli M, Cecere SC, Tambaro R, Attademo L. Pignata S, et al. Among authors: tambaro r. Cancer. 2019 Dec 15;125 Suppl 24:4609-4615. doi: 10.1002/cncr.32500. Cancer. 2019. PMID: 31967680 Free article. Review.
64 results